Abnormal lipid metabolism in adjuvant arthritic rats. 1989

Y Yamaguchi, and Y Tanaka, and K Yamada, and Y Bandô, and M Kunitomo
Department of Pharmacology, Faculty of Pharmaceutical Sciences, Mukogawa Women's University, Nishinomiya, Japan.

This study examined the altered lipid metabolism and effects of drug treatments during the development of adjuvant arthritis in rats. Before its onset (day 9 post-adjuvant), large decreases were noted in the serum total cholesterol, high-density lipoprotein (HDL) cholesterol and triglyceride levels and, in particular, a large decrease in the lecithin-cholesterol acyltransferase activity. A large increase in the serum phospholipid level was also noted. As the arthritis progressed, the serum total cholesterol and HDL-cholesterol levels were rapidly reversed, finally reaching a level significantly higher than normal, together with rises in the serum free-cholesterol and lipid peroxide levels. These changes in serum lipids and enzyme activity could be normalized by treatment with cyclophosphamide, an immunosuppressive agent, but other than the serum triglyceride level, were not affected by treatment with indomethacin, a nonsteroidal anti-inflammatory drug, despite the fact that both drug treatments almost completely suppressed the progression of arthritis. These findings suggest that the abnormal lipid metabolism induced by adjuvant injection is not associated with the inflammatory activity, but associated with the immunopathologic response.

UI MeSH Term Description Entries
D007213 Indomethacin A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. Amuno,Indocid,Indocin,Indomet 140,Indometacin,Indomethacin Hydrochloride,Metindol,Osmosin
D007862 Phosphatidylcholine-Sterol O-Acyltransferase An enzyme secreted from the liver into the plasma of many mammalian species. It catalyzes the esterification of the hydroxyl group of lipoprotein cholesterol by the transfer of a fatty acid from the C-2 position of lecithin. In familial lecithin:cholesterol acyltransferase deficiency disease, the absence of the enzyme results in an excess of unesterified cholesterol in plasma. Lecithin Cholesterol Acyltransferase,Cholesterol Ester Lysolecithin Acyltransferase,Lecithin Acyltransferase,Phosophatidylcholine-Sterol Acyltransferase,Acyltransferase, Lecithin,Acyltransferase, Lecithin Cholesterol,Acyltransferase, Phosophatidylcholine-Sterol,Cholesterol Acyltransferase, Lecithin,O-Acyltransferase, Phosphatidylcholine-Sterol,Phosophatidylcholine Sterol Acyltransferase,Phosphatidylcholine Sterol O Acyltransferase
D008054 Lipid Peroxides Peroxides produced in the presence of a free radical by the oxidation of unsaturated fatty acids in the cell in the presence of molecular oxygen. The formation of lipid peroxides results in the destruction of the original lipid leading to the loss of integrity of the membranes. They therefore cause a variety of toxic effects in vivo and their formation is considered a pathological process in biological systems. Their formation can be inhibited by antioxidants, such as vitamin E, structural separation or low oxygen tension. Fatty Acid Hydroperoxide,Lipid Peroxide,Lipoperoxide,Fatty Acid Hydroperoxides,Lipid Hydroperoxide,Lipoperoxides,Acid Hydroperoxide, Fatty,Acid Hydroperoxides, Fatty,Hydroperoxide, Fatty Acid,Hydroperoxide, Lipid,Hydroperoxides, Fatty Acid,Peroxide, Lipid,Peroxides, Lipid
D008076 Cholesterol, HDL Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol. High Density Lipoprotein Cholesterol,Cholesterol, HDL2,Cholesterol, HDL3,HDL Cholesterol,HDL(2) Cholesterol,HDL(3) Cholesterol,HDL2 Cholesterol,HDL3 Cholesterol,alpha-Lipoprotein Cholesterol,Cholesterol, alpha-Lipoprotein,alpha Lipoprotein Cholesterol
D008297 Male Males
D009161 Mycobacterium A genus of gram-positive, aerobic bacteria. Most species are free-living in soil and water, but the major habitat for some is the diseased tissue of warm-blooded hosts. Mycobacteria
D010743 Phospholipids Lipids containing one or more phosphate groups, particularly those derived from either glycerol (phosphoglycerides see GLYCEROPHOSPHOLIPIDS) or sphingosine (SPHINGOLIPIDS). They are polar lipids that are of great importance for the structure and function of cell membranes and are the most abundant of membrane lipids, although not stored in large amounts in the system. Phosphatides,Phospholipid
D011916 Rats, Inbred F344 An inbred strain of rat that is used for general BIOMEDICAL RESEARCH purposes. Fischer Rats,Rats, Inbred CDF,Rats, Inbred Fischer 344,Rats, F344,Rats, Inbred Fisher 344,CDF Rat, Inbred,CDF Rats, Inbred,F344 Rat,F344 Rat, Inbred,F344 Rats,F344 Rats, Inbred,Inbred CDF Rat,Inbred CDF Rats,Inbred F344 Rat,Inbred F344 Rats,Rat, F344,Rat, Inbred CDF,Rat, Inbred F344,Rats, Fischer
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271

Related Publications

Y Yamaguchi, and Y Tanaka, and K Yamada, and Y Bandô, and M Kunitomo
April 1996, Xenobiotica; the fate of foreign compounds in biological systems,
Y Yamaguchi, and Y Tanaka, and K Yamada, and Y Bandô, and M Kunitomo
February 1983, Research communications in chemical pathology and pharmacology,
Y Yamaguchi, and Y Tanaka, and K Yamada, and Y Bandô, and M Kunitomo
October 1986, Japanese journal of pharmacology,
Y Yamaguchi, and Y Tanaka, and K Yamada, and Y Bandô, and M Kunitomo
January 1986, Acta pharmacologica et toxicologica,
Y Yamaguchi, and Y Tanaka, and K Yamada, and Y Bandô, and M Kunitomo
January 1982, European journal of drug metabolism and pharmacokinetics,
Y Yamaguchi, and Y Tanaka, and K Yamada, and Y Bandô, and M Kunitomo
February 1986, Biochemical medicine and metabolic biology,
Y Yamaguchi, and Y Tanaka, and K Yamada, and Y Bandô, and M Kunitomo
March 2004, Inflammation research : official journal of the European Histamine Research Society ... [et al.],
Y Yamaguchi, and Y Tanaka, and K Yamada, and Y Bandô, and M Kunitomo
January 1989, Drug metabolism and disposition: the biological fate of chemicals,
Y Yamaguchi, and Y Tanaka, and K Yamada, and Y Bandô, and M Kunitomo
March 1967, Horumon to rinsho. Clinical endocrinology,
Y Yamaguchi, and Y Tanaka, and K Yamada, and Y Bandô, and M Kunitomo
February 1971, Naika. Internal medicine,
Copied contents to your clipboard!